Clinical Trials Sponsored by BioProtect

Total 37 results

BioProtect

Recruiting

Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System (CLP-10441)

Prostate Cancer

Ireland, Israel, Netherlands, Poland, Portugal
BioProtect

Completed

Retrospective Evaluation of Commercial Spacers in Prostate Cancer Patients (CLP-10095)

Prostate Cancer

Poland, Portugal
BioProtect

Completed

ProSpace™ Balloon System Pivotal Study BP-007

Prostate Cancer

United States, Israel, United Kingdom, Netherlands, Poland, Portugal
BioProtect

Completed

Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy

Prostate Cancer

Israel
BioProtect

Completed

Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects

Prostate Cancer

United States
BioProtect

Completed

Prospective Evaluation of a Commercially Available Hydrogel Spacer (BP-008)

Prostate Cancer

United States
BioProtect

Completed

Retrospective Evaluation of a Commercially Available Hydrogel Spacer (BP-009)

Prostate Cancer

United States
Bioprojet

Active, not recruiting

Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period

Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy

France, Italy, Russian Federation, Finland, Netherlands
Bioprojet

Completed

Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.

Treatment of Excessive Daytime Sleepiness in Narcolepsy

France
Bioprojet

Completed

Efficacy and Safety of BP1.4979 in Smoking Cessation

Tobacco Addiction

France
Bioprojet

Completed

Pharmacokinetics of BF2.649 in Renal Impairment

Renal Impairment

France
Bioprojet

Not yet recruiting

Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents

Autism Spectrum Disorder
Bioprojet

Recruiting

Pilot Study on BP1.4979 Effect on Binge Eating Disorders

Binge-Eating Disorder

France
Bioprojet

Terminated

Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (P13-04)

Restless Legs Syndrome

France
Bioprojet

Completed

Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA (HAROSA3)

Obstructive Sleep Apnea | Excessive Daytime Sleepiness

Bulgaria, North Macedonia
Bioprojet

Withdrawn

Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness (HAROSA IV)

Obstructive Sleep Apnea | Excessive Daytime Sleepiness

France
Bioprojet

Completed

Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)

Excessive Daytime Sleepiness | Narcolepsy With Cataplexy

Hungary
Bioprojet

Completed

BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. (HAROSA2)

Obstructive Sleep Apnea | Excessive Daytime Sleepiness

France
Bioprojet

Completed

Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)

Excessive Daytime Sleepiness | Obstructive Sleep Apnoea

France
Bioprojet

Completed

Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

Parkinson's Disease | Excessive Daytime Sleepiness

France
Bioprojet

Recruiting

Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke

Fatigue

France, Switzerland
Bioprojet

Completed

Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment

Alcohol Use Disorder

France, Bulgaria, Russian Federation
Bioprojet

Completed

Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users

Healthy | Drug Abuse

Canada
Bioprojet

Completed

Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) (HARMONYIII)

Narcolepsy | Cataplexy

France
Bioprojet

Withdrawn

A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment (PoC Alcohol)

Alcohol Abuse, Nervous System
Bioprojet

Completed

Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy Male Volunteers

Healthy Volunteers
Bioprojet

Completed

Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) (HARMONY IV)

Narcolepsy

France
Bioprojet

Completed

BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS (HAROSA1)

Obstructive Sleep Apnea | Excessive Daytime Sleepiness

France
Bioprojet

Terminated

First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375

Healthy Male Volunteers

Netherlands
Bioprojet

Completed

Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules

Healthy Male Volunteers

France
Bioprojet

Completed

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease (HARPS1)

Parkinson's Disease

France
Bioprojet

Completed

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease (HARPS2)

Parkinson's Disease

Germany
Bioprojet

Completed

Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy (Harmony2)

Narcolepsy | Cataplexy | Excessive Daytime Sleepiness

Switzerland
Bioprojet

Completed

Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy (Harmony1)

Sleep Disorders | Narcolepsy | Cataplexy | Excessive Daytime Sleepiness

Switzerland
Sun Yat-sen University
Doublle Bioproduct Inc

Unknown

Trial of E10A in Head and Neck Cancer

Nasopharyngeal Carcinoma | Head and Neck Squamous Carcinoma

China
Sun Yat-sen University
Doublle Bioproduct Inc

Unknown

Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor

Advanced Solid Tumor

China
University of Texas Southwestern Medical Center
Stanley Medical Research Institute; Bioprojet

Completed

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

Schizophrenia

United States

3

Subscribe